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Summary:  
The prevalence of serum antibodies against C. difficile (CD) toxins A and B in 
healthy populations have prompted interest in evaluating the therapeutic activity 
of intravenous immunoglobulin (IVIg) in individuals experiencing severe or 
recurrent C. difficile infection (CDI). Despite some promising case reports, a 
definitive clinical role for IVIg in CDI remains unclear. Contradictory results may 
be attributed to a lack of consensus regarding optimal dose, timing of 
administration and patient selection as well as variability in specific antibody 
content between commercial preparations. The purpose of this study was to 
retrospectively investigate the efficacy of three commercial preparations of IVIg 
for treating severe or recurrent CDI. In subsequent mechanistic studies using 
protein microarray and toxin neutralization assays, all IVIg preparations were 
analyzed for specific binding and neutralizing antibodies (NAb) to CD antigens 
in vitro and the presence of anti-toxin NAbs in vivo following IVIg infusion. A 
therapeutic response to IVIg was observed in 41% (10/17) of the CDI patients. 
Significant variability in multi-isotype specific antibodies to a 7-plex panel of CD 
antigens and toxin neutralization efficacies were observed between IVIg 
preparations and also in patient sera before and after IVIg administration. 
These results extend our current understanding of population immunity to CD 
and support the inclusion of surface layer proteins and binary toxin antigens in 
CD vaccines. Future strategies could enhance IVIg treatment response rates by 
using protein microarray to preselect donor plasma/serum with the highest 
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levels of anti-CD antibodies and/or anti-toxin neutralizing capacities prior to 
fractionation. 
Introduction:  
Clostridium difficile (CD) is the leading cause of hospital-acquired infective 
diarrhoea and a global health problem [1]. CD exerts its major pathological 
effects through two pro-inflammatory and cytotoxic protein exotoxins, A and B. 
Some strains also produce a third protein toxin known as binary toxin or CDT. 
Non-toxin virulence factors such as surface layer proteins (SLPs) also appear to 
be involved in pathogenesis [2-5]. Several clinical studies have previously 
reported associations between the  ability to mount serum antitoxin antibody 
responses, favorable clinical outcome and the absence of CDI recurrence [6-
10].  
Early population prevalence studies also indicate that the majority of healthy 
adults have detectable antibodies to CD toxins A and B in their sera that are 
thought to arise from colonization in infancy or from repeated environmental 
exposure to CD in adulthood [11-12]. For this reason, polyclonal IVIg has been 
used off-label to treat both recurrent and fulminant C. difficile infection (CDI). 
Human intravenous immunoglobulin (IVIg) consists of purified plasma 
immunoglobulins from hundreds to thousands of healthy blood donors. 
Although several encouraging case reports highlight the potential benefits of 
IVIg, its definitive clinical role is still unclear, mainly due to the lack of robust 
evidence from randomized controlled trials [13-16]. Contradictory results 
obtained in respect to its clinical efficacy may be in part ascribed to the poor 
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characterization of commercial IVIg preparations in terms of their specific 
antibody content.  
The mode of action of IVIg remains poorly understood. While some attention 
has focused on the varying capacity of IVIg to treat recurrent CDI, presumably 
by neutralizing CD toxins A and B [13], the full repertoire of CD-associated 
protein targets of these complex preparations remain ill-defined, as do the 
subclass distribution of these specific antibodies. Furthermore, the exact 
prevalence, kinetics and individual variation of binding and neutralizing 
antibodies (NAb) against CD proteins in serum samples, including those 
exposed to IVIg, are poorly described. Microarray assays are a promising new 
tool for compositional bioanalysis of specific antibody content in patient sera 
and IVIg due to their high sensitivity, reproducibility and ease of use. We have 
determined whether the IVIg products used in our institution possess specific 
binding and neutralizing antibodies to CD antigens in vitro and whether anti-
toxin NAbs are present in vivo following IVIg infusion. 
Materials and Methods: 
Patients and samples: We retrospectively investigated the efficacy of three 
commercial preparations of IVIg (Vigam® BPL, Privigen® CSL Behring and 
Intratect® Biotest UK)  in the treatment of adult patients with protracted, 
recurrent or severe CDI at Nottingham University Hospitals NHS Trust between 
2012 and 2015. CDI cases (Cohort 1) were defined as patients with diarrhea (at 
least three loose stools per day for at least two consecutive days) and 
cytotoxin-positive feces. Medical records were reviewed for the following data: 
patient demographics, disease severity (ZAR score) [16, 17], previous CDI 
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treatment, IVIg type, timing (days from diarrhea to infusion), dosage and 
response to treatment, complications of IVIg therapy, need for colectomy, in-
hospital mortality and CARDS risk of death score [18]. For Cohort 1, stored 
serum samples were not available for serological analysis. We therefore 
profiled sera from patients (Cohort 2) before and immediately after 
administration of IVIg treatment for combined immunodeficiency disorder [CVID; 
n=5 (47 (41-68 years)], chronic inflammatory demyelinating polyneuropathy 
(CIDP; n=1; 65 years of age) and CDI (n=1, 71 years of age). All subjects 
provided written informed consent under approvals granted by the Nottingham 
Research Ethics Committee.  
Antigen Microarray: Binding of antibodies within IVIg preparations and patient 
sera to specific CD antigens were determined by using a previously validated 
CD protein microarray [19].  In brief, seven CD antigens, two positive controls: 
tetanus toxoid and lysates from Candida albicans, a negative control (printing 
buffer) and 10-point two-fold serial dilutions of human immunoglobulin 
(matching the tested antibody isotype) were spotted onto aminosilane slides 
(Schott, Germany) in quadruplicates using MicroGridII arrayer (Digilab, USA) 
and a silicon contact pin (Parallel Synthesis Technologies, USA). The seven CD 
antigens used in this study were: highly purified CD whole toxins A (200μg/mL) 
and B (100μg/mL; toxinotype 0, strain VPI 10463, ribotype 087), toxin B from a 
CD toxin-B only expressing strain (CCUG 20309; 90μg/mL), precursor form of B 
fragment of binary toxin, pCDTb, (200μg/mL; produced from a wholly synthetic 
recombinant gene construct; amino acid sequence based on published 
sequence from 027 ribotype http://www.uniprot.org/uniprot/A8DS70) and 
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purified native whole ribotype-specific (001, 002, 027) surface layer proteins 
(SLPs; all 200μg/mL). Multi-isotype (IgG, IgG1, IgG2, IgG3, IgG4, IgA, IgA1, 
IgA2 and IgM) antibody levels in serum samples and in IVIg preparations were 
tested against the CD panel of antigens. Slides were scanned at 635nm and the 
resultant images were processed with Genepix Pro-6 Microarray Image 
Analysis software (Molecular Devices Inc.). Protein signals were determined 
after background subtraction though customized modules in the R statistical 
language to generate general mean of signal levels. Specific isotype responses 
were interpolated against the internal isotype standard curve for each sample. 
Antibody Neutralization Assay:  
A Caco-2 cell-based assay for anti-toxin A and anti-toxin B NAb was used as 
previously published [20]. Briefly, Caco-2 cells (HTB-37; ATCC) were 
maintained in minimal essential medium (MEM) plus 20% fetal calf serum, 2mM 
glutamine and nonessential amino acids at 37°C. Serum samples were diluted 
in the assay medium at three dilutions (1:10, 1:100 and 1:1000). Then premixed 
with toxin A or toxin B (at 50% lethal dose [LD50]) for 1h at 37°C before 50μL of 
this mixture was transferred to the cells and incubated for 96 h. Following 
aspiration of the medium, 50μL methylene blue (0.5% [wt/vol] dissolved in 50% 
[vol/vol] ethanol) was added to the cell culture and incubated for 1h at room 
temperature. Then, the cells were washed gently with tap water (to remove 
excess stain) and air dried. The cells were then lysed by adding 100μL 1% 
(vol/vol) N-lauryl-sarcosine and incubated on a shaker for 15 minutes at room 
temperature. The cell biomass was determined by measuring the absorbance of 
each well on a BioTek Synergy2 (BioTeK, USA) plate reader at 405nm. Toxin 
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activity and working LD50 concentrations were defined empirically in 
preliminary experiments and for each individual batch/lot of toxin used. 
Statistical analysis  
All statistical analyses were performed on natural log-transformed data using 
GraphPad Prism version 6 (GraphPad software, San Diego, CA). For non-
paired data and multiple comparisons, the one-way ANOVA test was applied. 
For paired data, the Wilcoxon signed-rank test was used. Demographic data 
were presented as median and ranges. A p value ≤0.05 was deemed 
statistically significant. 
Results: 
Before IVIg treatment, all patients in Cohort 1 had received high dose oral 
vancomycin (500mg four-times daily) and intravenous metronidazole (500mg 
four-times daily). All patients received 0.4g/kg of IVIg. Compared with non-
responders [n=10/17; 75 (58-85) years], responders to IVIg [n=7/17; 82 (50-90) 
years] had lower ZAR disease severity [3(1-6) vs 5 (2-8), p= 0.14], CARDS risk 
of death scores [6 (3-15) vs 10.5 (2-14), p=3.1] and inpatient mortality [3 of 7 vs 
7 of 10)], although these findings did not reach statistical significance. There 
were no statistically significant differences between the treatment response 
subgroups in the type of preparation, timing of administration or number of IVIg 
infusions received. No complications were reported for IVIg. Two patients 
underwent urgent colectomy in the non-responder group. 
Specific antibody reactivities against CD proteins varied between the different 
commercial IVIg preparations as shown in the heatmap in figure 1A. Briefly, all 
IVIg preparations showed IgG reactivity to all tested CD antigens, although a 
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weaker response was observed to the SLPs. Vigam contained significantly 
higher levels of IgG1 antibodies against all toxins compared with Privigen and 
Intratect. Moreover, the antibody neutralization assay showed variability in 
percentage protection against CD toxins A and B between the different IVIg 
preparations. Here, Intratect at a 1:100 titration demonstrated a significantly 
lower protective capacity to neutralize CD toxin A compared with Vigam and 
Privigen (figure 1B).  
For Cohort 2, the microarray data showed post-IVIg infusion enhancement in 
the levels of total IgG, IgG1, IgG2 and IgG3 to CD antigens (native toxins A and 
B, both VPI 10463), binary toxin (pCDTb) and toxin B (CCUG 20309), in all 
patients’ sera (figure 2A). A statistically significant increase (p<0.05) was 
observed in the levels of total IgG against all toxins tested following IVIg 
administration (figure 2B). Notably, the highest IgG binding response was 
against toxin B (p = 0.0006, data not shown). However, there was no difference 
in post-IVIg NAb responses between toxins A and B (p= 0.0728, data not 
shown). For IgG1, this increase was significant against toxin B, binary toxin 
(pCDTb) and toxin B (CCUG 20309) only. Moreover, IgG2 antibody levels were 
significantly increased (p<0.05) against toxin B, and toxin B (CCUG 20309). 
Interestingly, following IVIg infusion, the level of IgG3 was increased against 
toxin A, toxin B, toxin B (CCUG 20309), and SLP027, but the magnitude was 
not statistically significant. Serum samples from all cohort 2 patients after IVIg 
infusion demonstrated significantly enhanced anti-toxin A and anti-toxin B 
antibody neutralization activities (figure 2C) at 1:10 dilution. However, the 
antitoxin NAb effect was reduced at higher serum dilutions (data not shown).  
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Discussion:  
Although no patients in either cohort experienced complications attributable to 
IVIg therapy, only 41% of the CDI patients in Cohort 1 showed a therapeutic 
response to IVIg with two patients requiring emergency colectomy for fulminant 
CDI in the non-responder group. These findings are in keeping with an earlier 
observational study by Abougergi et al [9] which revealed that 43% of patients 
survived their hospitalization with CDI colitis resolution following IVIg. These 
observations may reflect inadequate dosaging, delayed treatment, insufficient 
binding and/or neutralizing titers and more severe disease. Importantly, our 
findings do show the limited efficacy of Intratect in neutralizing toxin A and 
suggest that Vigam or Privigen may be the preferred IVIg preparation of choice 
for use in the CDI population. 
We believe this is the first report that demonstrates the prevalence of CD anti-
binary toxin and anti-SLP antibodies in all tested human IVIg preparations and 
in patient sera pre- and post IVIg treatment. Our data also confirm the detection 
of protective anti-toxin A and anti-toxin B NAbs in patient sera following 
treatment. Variability in specific antibody content between the different IVIg 
preparations examined in this study and that reported in an earlier study by 
Salcedo et al [1] may be due to the different geographical regions from which 
the plasma samples were collected and/or differences in CD exposure. Our 
binding data for IgG revealed significantly higher levels of anti-toxin B IgG in 
post IVIg sera. This finding seems to confirm the recent Merck monoclonal 
antibody Phase 3 trial which showed that an anti-toxin B response was the 
prime determinant for preventing CDI relapse [21]. Enhanced IgG2 and IgG3 
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immunoreactivites seen following IVIg infusion may prove highly beneficial 
given their more desirable molecular and functional attributes. Indeed, Katchar 
et al [22] detected humoral immune deficiencies in the IgG2 and IgG3 
subclasses directed towards toxin A in patients with recurrent CDI. The lack of a 
post-IVIg IgG4 response is perhaps indicative that the immune response has 
not been pushed through to repeat antigen challenge. Differences in observed 
toxin neutralizing efficiencies might be caused by a combination of anti-toxin 
antibody titers, as well as by individual differences in toxin potencies. 
Interestingly, none of the CVID and CIDP patients receiving three weekly IVIg 
infusions in Cohort 2 had previously developed CDI. This may be because of 
protective anti-toxin NAb in the IVIg. Although most CD protein toxins should be 
neutralized by IVIg treatment, we were unable to study anti-binary neutralizing 
capacities within the IVIg or patient sera. Moreover, we did not examine 
antibody affinities for the CD antigens described in this report. Although there 
were no stored sera available for Cohort 1, we did compare binding and NAbs 
pre- and post-infusion in a second mainly non-CDI cohort. It is noteworthy that 
the diarrheal symptoms of the CDI patient that received IVIg in Cohort 2 
resolved within 4 days of IVIg (Privigen) infusion. 
These results might be helpful for optimizing the type and dosage of IVIg used 
in adjunctive therapy for CDI, and further support a possible rationale for 
inclusion of SLPs and binary toxin antigens in future candidate CD vaccines. 
Further studies are required to measure antibody affinities and to clarify the 
precise contribution of different IgG subclasses to clinical protection or to 
disease pathogenesis. These studies could be achieved by purifying out the 
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IgG subclass-specific antibodies and assessing their significance (including 
their potential to interfere with or block the action of other IgG subclasses) in 
well-validated functional assays [23]. For example, an early study compared 
purified subclass antibodies in Herpes virus neutralization assays, determining 
that IgG3 and IgG4 had the greatest viral neutralizing ability despite not being 
the predominant subclass [24]. A further study of responses against human 
enterovirus 71 found that IgG1 and IgG2 fractions were the most effective at 
neutralization, and that IgG3 led to enhanced infection [25]. The knowledge 
obtained from IgG subclass studies, combined with a greater molecular 
understanding of IgG subclass properties will facilitate the engineering and 
development of highly effective CD-specific monoclonal therapeutic antibodies. 
Despite ongoing debate as to the utility of IVIg for CDI, future strategies could 
attempt to enhance the opportunities of this drug to show therapeutic efficacy 
and survival through application of disease severity risk scores, which should 
prompt earlier identification of those patients who are likely to require and 
receive most benefit from IVIg [17-18]. A review of the severe cases of CDI 
published in the medical literature suggests that the earlier administration of 
IVIg may increase the likelihood of attaining therapeutic efficacy and survival 
[16]. Moreover, given that the concentration and antimicrobial specificities of the 
antibodies are not normally routinely evaluated in batches of commercial 
polyclonal IVIg, donor units delivered to the fractionation sites that have high 
antibody levels against CD antigens could be identified using microarray 
technology and stored in biobanks. Donor plasma/serum could even be 
prescreened before donation to identify optimal batches with the highest levels 
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of CD-reactive IgG. Alternatively, the anti-CD activity of IVIg could be further 
enhanced by acquiring blood samples from patients convalescing from CDI or 
from vaccinated individuals. Such an enrichment strategy has been successfully 
used to treat viral diseases [26-28], and is regarded by WHO as a potential 
treatment for Ebola Virus Disease [29]. While the breadth of protection may still 
be limited by ribotype or strain-specific differences in protein expression, hyper-
immune IVIg (H-IVIg) may represent a more effective adjunct for CDI than the 
polyspecific IVIg that is currently employed clinically. This therapy should be 
studied in a head to head comparison with polyclonal IVIg and antitoxin levels 
within patient sera should be correlated with clinical outcomes. 
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Figure Legends: 
Figure 1: Immune reactivity and neutralizing effect of IVIg to C. difficile 
antigens. 
A) Reactivity of multi-isotype specific antibodies to C. difficile antigens in 
commercial IVIg preparations: Heatmap produced by Multiple Experiment 
Viewer (MeV 4.9) illustrates the levels of specific antibody isotypes (IgG, IgG1, 
IgG2, IgG3, IgG4, IgA, IgA1, IgA2 and IgM) in three commercially available IVIg 
preparations; Vigam, Privigen and Intratect, against seven C. difficile antigens 
[toxin A (200μg/mL, toxin B (100μg/mL), pCDTb (200μg/mL), toxin B (CCUG 
20309; 90μg/ml) and surface layer proteins (SLPs) 001, 002, and 027; all 
200μg/mL] using protein microarray technology. Colour code of the heatmap: 
green (low) to red (high) signal intensity. Signal values represented on the 
colour scale for the heatmap are log2 transformed from the arbitrary 
fluorescence units (AFU).  Total IgG, IgG1 and IgG2 isotypes gave the highest 
binding reactivities against toxin A, toxin B, binary toxin (pCDTb) and toxin B 
(CCUG 20309).  
B) IVIg neutralization efficacy against C. difficile native whole toxins toxin 
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A and toxin B: Percentage protective neutralization effect of commercial IVIg 
products; Vigam, Privigen and Intratect against C.difficile toxins A and B. Each 
plot represents the median of triplicate experiments at 1:100 dilution. Intratect 
exhibits the lowest protective effect compared to Vigam and Privigen, 
particularly against toxin A. P values of **** ≤0.0001; * ≤0.05 (one-way 
ANOVA). 
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Figure 2: Immune reactivity and neutralizing effect of patients’ sera to C. 
difficile antigens. 
A) Comparison of antibody reactivities against C. difficile proteins in 
patients sera before and after IVIg infusion: Heatmap produced by Multiple 
Experiment Viewer (MeV 4.9) illustrates the expression level of the isotypes 
(IgG, IgG1, IgG2, IgG3IgG4, IgA, IgA1, IgA2 and IgM) in serum samples  in 7 
patients before and after IVIg infusion against seven C.difficile antigens [Toxin 
A (200μg/mL), Toxin B (100μg/mL), pCDTb (200μg/mL), Toxin B (CCUG 
20309; 90μg/mL) and surface layer proteins (SLPs) 001, 002, and 027; all 
200μg/mL] using protein microarray technology. Colour code of the heatmap: 
green (low) to red (high) signal intensity. Signal values represented on the 
colour scale for the heatmaps are log2 transformed from the arbitrary 
fluorescence units (AFU). There was post infusion enhancement of the total 
IgG, IgG1, IgG2 and IgG3 reactivities to Toxin A, Toxin B, and pCDTb.  
B) IgG responses to toxins A, B and binary toxin (pCDTb) pre- and post-
IVIg administration. Pre- and post-IVIg IgG anti-toxin levels showing 
significant increase of total IgG against all toxins tested following IVIg infusion 
(Wilcoxon signed-rank test). Each plot represents the median of triplicate 
experiments at 1:10 dilution. 
C) Neutralisation effect against C. difficile native toxins A and B following 
IVIg administration: Comparison of pre- and post-infusion neutralizing 
antibody acitivites showed enhanced protective effect after IVIg infusions 
against C. difficile native toxins (toxin A and toxin B). Each plot represents the 
median of triplicate experiments at 1:10 dilution. A significant increase in the 
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protective effect against toxin A and toxin B was noted in patient sera tested 
post IVIg infusion (Wilcoxon signed-rank test). 
 
